IMRX
$4.80
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
Intraday
Recent News
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts. All three names carry verified Buy or Overweight ratings, and the gap between current trading prices and analyst targets ranges from substantial to dramatic. Three Calls, Three Catalysts ... X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3
Immuneering (NASDAQ:IMRX) Chief Executive Officer and co-founder Ben Zeskind told attendees at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference that the company is focused on improving survival in first-line pancreatic cancer and “beyond,” led by its oral MEK inhibitor candidate atebime
Director of Immuneering Picks Up 1.8% More Stock
Even if it's not a huge purchase, we think it was good to see that Peter Feinberg, the Director of Immuneering...
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition
Immuneering (IMRX) has attracted fresh attention after reporting updated Phase 2a data for atebimetinib in first line pancreatic cancer, showing 64% 12 month overall survival and plans to move into a pivotal Phase 3 trial. See our latest analysis for Immuneering. Despite the strong clinical update, Immuneering’s latest share price of $4.66 comes after a 30 day share price return of a 23% decline and a 7 day share price return of a 30% decline. This contrasts with a very large 1 year total...
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next
Immuneering Corporation has reported updated Phase 2a data showing atebimetinib plus modified gemcitabine/nab-paclitaxel achieved 64% overall survival at 12 months in first-line pancreatic cancer patients, with no new safety signals identified as of the December 15, 2025 cutoff. A key nuance is that these results, though compared against MPACT standard-of-care benchmarks, come from a relatively small 34-patient, non–head-to-head trial that will now inform the design of the planned pivotal...